| TITLE |
DATE |
| Jazz Pharmaceuticals Announces Presentations at Investor Conferences in November |
9-Nov-2011 |
| Jazz Pharmaceuticals Announces Third Quarter 2011 Financial Results |
1-Nov-2011 |
| Jazz Pharmaceuticals Announces Third Quarter 2011 Results Conference Call on November 1 |
20-Oct-2011 |
| Jazz Pharmaceuticals Appoints Head of Research and Development |
27-Sep-2011 |
| Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz Pharmaceuticals plc |
19-Sep-2011 |
| Jazz Pharmaceuticals Announces Presentation at the UBS Global Life Sciences Conference in New York on September 20 |
16-Sep-2011 |
| Jazz Pharmaceuticals Announces Second Quarter 2011 Financial Results |
28-Jul-2011 |
| Jazz Pharmaceuticals Announces Second Quarter 2011 Results Conference Call on July 28 |
12-Jul-2011 |
| Jazz Pharmaceuticals Announces Presentation at the Jefferies 2011 Global Healthcare Conference in New York on June 8 |
2-Jun-2011 |
| Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results |
3-May-2011 |
| Jazz Pharmaceuticals Announces First Quarter 2011 Results Conference Call on May 3 |
21-Apr-2011 |
| Jazz Pharmaceuticals to Present at Upcoming Investor Conferences |
8-Mar-2011 |
| Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results |
7-Mar-2011 |
| Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results Conference Call on March 7 |
28-Feb-2011 |
| Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1 |
23-Feb-2011 |
| Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 12 |
5-Jan-2011 |
| Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate |
21-Dec-2010 |
| Jazz Pharmaceuticals Announces Presentation at the Lazard Capital Markets Healthcare Conference on November 17 |
11-Nov-2010 |
| Jazz Pharmaceuticals Announces Adjusted Net Income for the Third Quarter of $0.41 per Share and GAAP Net Income of $0.32 per Share |
4-Nov-2010 |
| Jazz Pharmaceuticals Announces November 4 Conference Call to Discuss Third Quarter 2010 Results and Guidance |
28-Oct-2010 |
| Jazz Pharmaceuticals Receives FDA Complete Response Letter Regarding JZP-6 for Treatment of Fibromyalgia |
11-Oct-2010 |
| Jazz Pharmaceuticals Announces Paragraph IV ANDA Filing for Xyrem |
5-Oct-2010 |
| Jazz Pharmaceuticals to Present at the UBS Global Life Sciences Conference on September 20 |
14-Sep-2010 |
| Jazz Pharmaceuticals Provides Update on FDA Advisory Committee Meeting For JZP-6 (Sodium Oxybate) in Fibromyalgia |
20-Aug-2010 |
| Jazz Pharmaceuticals Announces Second Quarter 2010 Financial Results |
10-Aug-2010 |
| Jazz Pharmaceuticals to Present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference |
6-Aug-2010 |
| Jazz Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 10 |
2-Aug-2010 |
| Jazz Pharmaceuticals Announces Completion of Refinancing of its 15% Senior Secured Notes Due June 2011 With Closing of $50 Million Term Loan Due June 2013 |
30-Jun-2010 |
| Jazz Pharmaceuticals' JZP-6 to be Reviewed at a Joint Meeting of the FDA's Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on August 20, 2010 |
24-Jun-2010 |
| Paul L. Berns Joins Jazz Pharmaceuticals' Board of Directors |
7-Jun-2010 |
| Jazz Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference |
1-Jun-2010 |
| Jazz Pharmaceuticals Announces Pricing of Public Offering of Common Stock |
11-May-2010 |
| Jazz Pharmaceuticals Announces Public Offering of Common Stock |
10-May-2010 |
| Jazz Pharmaceuticals Announces First Quarter 2010 Financial Results |
5-May-2010 |
| Rick E. Winningham Joins Jazz Pharmaceuticals' Board of Directors |
5-May-2010 |
| Jazz Pharmaceuticals to Announce First Quarter 2010 Financial Results on May 5, 2010 |
28-Apr-2010 |
| Jazz Pharmaceuticals to Present at Deutsche Bank's 35th Annual Health Care Conference |
26-Apr-2010 |
| Jazz Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference |
16-Mar-2010 |
| Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results |
3-Mar-2010 |
| Jazz Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 3, 2010 |
23-Feb-2010 |
| Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia |
18-Feb-2010 |
| Jazz Pharmaceuticals to Present at 2010 J.P. Morgan Healthcare Conference |
7-Jan-2010 |
| Jazz Pharmaceuticals Submits New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia |
15-Dec-2009 |
| Jazz Pharmaceuticals Appoints Kathryn Falberg as Chief Financial Officer |
3-Dec-2009 |
| Jazz Pharmaceuticals to Present at Investor Conference |
10-Nov-2009 |
| Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results |
5-Nov-2009 |
| Jazz Pharmaceuticals to Announce Third Quarter Financial Results on November 5, 2009 |
29-Oct-2009 |
| Data from Jazz Pharmaceuticals' First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences |
14-Oct-2009 |
| Jazz Pharmaceuticals to Present at Two Upcoming Investor Conferences |
3-Sep-2009 |
| Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results |
11-Aug-2009 |
| Jazz Pharmaceuticals to Announce Second Quarter Financial Results on August 11, 2009 |
10-Aug-2009 |
| Jazz Pharmaceuticals Pays Accrued Interest Under Senior Secured Notes |
7-Jul-2009 |
| Jazz Pharmaceuticals Completes $7 Million Private Placement |
7-Jul-2009 |
| Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints |
24-Jun-2009 |
| Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia |
15-Jun-2009 |
| Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia |
9-Jun-2009 |
| Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results |
7-May-2009 |
| Jazz Pharmaceuticals, Inc. Announces Board of Directors and Management Changes |
2-Apr-2009 |
| Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results |
26-Mar-2009 |
| Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia |
13-Jan-2009 |
| Jazz Pharmaceuticals Announces Issuance of Key Patent for Once-A-Day LUVOX CR(R) |
18-Dec-2008 |
| Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations |
16-Dec-2008 |
| Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia |
20-Nov-2008 |
| Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference |
19-Nov-2008 |
| Jazz Pharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results |
13-Nov-2008 |
| Jazz Pharmaceuticals, Inc. to Announce Third Quarter Financial Results on November 13, 2008 |
10-Nov-2008 |
| Jazz Pharmaceuticals to Present at Investor Conferences |
4-Nov-2008 |
| Jazz Pharmaceuticals to Present at Natixis Bleichroeder Hidden Gems Healthcare Conference |
6-Oct-2008 |
| Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia |
11-Sep-2008 |
| Jazz Pharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results |
7-Aug-2008 |
| Jazz Pharmaceuticals, Inc. to Announce Second Quarter Results on August 7, 2008 |
24-Jul-2008 |
| Jazz Pharmaceuticals Announces Closing of Registered Direct Offering |
21-Jul-2008 |
| Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering |
16-Jul-2008 |
| Jazz Pharmaceuticals Announces Development Timeline Updates |
11-Jun-2008 |
| Jazz Pharmaceuticals Files Form S-3 Registration Statements |
11-Jun-2008 |
| Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia |
2-Jun-2008 |
| Jazz Pharmaceuticals to Present at Investor Conferences |
16-May-2008 |
| Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results |
13-May-2008 |
| Jazz Pharmaceuticals to Present at Citigroup Healthcare Forum |
9-May-2008 |
| Jazz Pharmaceuticals, Inc. Secures $75 Million Committed Equity Financing Facility |
8-May-2008 |
| Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008 |
7-May-2008 |
| Jazz Pharmaceuticals to Present at Morgan Stanley Conference |
23-Apr-2008 |
| Jazz Pharmaceuticals' LUVOX CR Is Now Available for Patients With Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) |
14-Apr-2008 |
| Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt |
18-Mar-2008 |
| Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation |
13-Mar-2008 |
| Jazz Pharmaceuticals to Present at Healthcare Conferences |
11-Mar-2008 |
| Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting |
6-Mar-2008 |
| FDA Approves LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) |
28-Feb-2008 |
| Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results |
13-Feb-2008 |
| Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008 |
6-Feb-2008 |
| Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR |
31-Jan-2008 |
| Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate |
7-Jan-2008 |
| FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) |
21-Dec-2007 |
| Jazz Pharmaceuticals to Present at Lazard Healthcare Conference |
15-Nov-2007 |
| Updated Presentation Time -- Jazz Pharmaceuticals to Present at Credit Suisse Healthcare Conference |
13-Nov-2007 |
| Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results |
6-Nov-2007 |
| Jazz Pharmaceuticals to Present at Credit Suisse Healthcare Conference |
1-Nov-2007 |
| Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007 |
24-Oct-2007 |
| Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors |
8-Oct-2007 |
| Jazz Pharmaceuticals to Present at Natixis Bleichroeder's Hidden Gems Conference |
26-Sep-2007 |
| Jazz Pharmaceuticals to Present at UBS Global Life Sciences Conference |
11-Sep-2007 |
| Jazz Pharmaceuticals, Inc. Announces Second Quarter 2007 Financial Results |
9-Aug-2007 |
| Jazz Pharmaceuticals, Inc. Announces Submission of Complete Responses to FDA Approvable Letters for Luvox(R) CR and Luvox(R) |
2-Aug-2007 |
| Jazz Pharmaceuticals, Inc. to Announce Second Quarter 2007 Financial Results on August 9, 2007 |
26-Jul-2007 |
| Jazz Pharmaceuticals Announces Settlement of Government Investigation |
13-Jul-2007 |
| Jazz Pharmaceuticals, Inc. Announces Initial Public Offering |
31-May-2007 |
| JAZZ PHARMACEUTICALS LAUNCHES SLEEP MEDICINE FELLOWSHIP GRANT PROGRAM |
26-Mar-2007 |
| JAZZ PHARMACEUTICALS SUPPORTS NARCOLEPSY NETWORK INITIATIVE TO LAUNCH THE NATIONAL NARCOLEPSY AWARENESS CAMPAIGN |
5-Mar-2007 |
| JAZZ PHARMACEUTICALS, INC. AND SOLVAY PHARMACEUTICALS, INC. ANNOUNCE LICENSE AGREEMENT FOR LUVOX® (FLUVOXAMINE MALEATE) TABLETS AND FLUVOXAMINE MALEATE EXTENDED-RELEASE CAPSULES IN THE UNITED STATES |
1-Feb-2007 |
 |
